Related Experiment Videos
Iseganan HCl: a novel antimicrobial agent
Francis J Giles1, Rebecca Redman, Salim Yazji
1The University of Texas, MD Anderson Cancer Center, Department of Leukaemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA. fgiles@mdanderson.org
Abstract:
Iseganan HCl is an antimicrobial peptide under development for the prevention of oral mucositis, a severe consequence of some chemotherapy and radiation therapy regimens. Several attributes of iseganan make it an optimal candidate for study in this clinical situation where both local and systemic host defenses may be impaired. These include broad spectrum and rapid bactericidal activity, a lack of observed resistance and cross-resistance and stability in biological fluids. Clinical trials of patients receiving stomatotoxic chemotherapy followed by a haematopoietic stem cell transplant show iseganan reduces the occurrence of oral mucositis and ameliorates sequelae such as mouth pain, throat pain and difficulty swallowing. Iseganan is well-tolerated, which is partly attributable to a lack of systemic absorption following topical oral administration. Other promising areas of investigation include topical oral application for the prevention of ventilator-associated pneumonia and nebulisation for treatment of chronic lung infection in patients with cystic fibrosis. Future studies will expand on the role of iseganan as a novel antimicrobial.
Insights
Iseganan HCl, an antimicrobial peptide, effectively prevents and reduces oral mucositis in patients undergoing chemotherapy and stem cell transplants. This novel antimicrobial is well-tolerated and shows promise for other infections.
Area of Science:
- Antimicrobial Peptides
- Clinical Pharmacology
- Oncology Supportive Care
Background:
- Oral mucositis (OM) is a debilitating side effect of cancer therapies, impairing local and systemic host defenses.
- Iseganan HCl possesses broad-spectrum bactericidal activity, stability in biological fluids, and no observed resistance, making it suitable for compromised host conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of Iseganan HCl for the prevention and amelioration of oral mucositis.
- To explore other potential applications of Iseganan HCl in managing infections.
Main Methods:
- Clinical trials involving patients receiving stomatotoxic chemotherapy followed by hematopoietic stem cell transplant.
- Topical oral administration of Iseganan HCl.
Main Results:
- Iseganan HCl significantly reduced the occurrence of oral mucositis.
- It also ameliorated associated symptoms like mouth pain, throat pain, and dysphagia.
- The agent was well-tolerated with no systemic absorption observed.
Conclusions:
- Iseganan HCl is a promising therapeutic agent for preventing and managing oral mucositis in cancer patients.
- Its favorable safety profile and broad antimicrobial activity suggest potential for other indications, including ventilator-associated pneumonia and cystic fibrosis lung infections.